The TNT trial reported greater efficacy of a platinum than a taxane for BRCA1/2 PV carriers with metastatic hormone receptor (HR)–negative, HER2-negative (also known as triple-negative) breast cancer (TNBC) (4). The gene discussed is BRCA1; the disease is breast cancer.